Anifrolumab real-world treatment outcomes in systemic lupus erythematosus - SLE-ARTEMIS
Study identifier:D3461R00082
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Will Be Recruiting
Official Title
Anifrolumab real-world treatment outcomes in Polish patients with systemic lupus erythematosus (SLE). Multicenter, non-interventional study
Medical condition
Lupus Erythematosus, Systemic
Phase
N/A
Healthy volunteers
No
Study drug
Anifrolumab
Sex
All
Estimated Enrollment
100
Study type
Observational
Age
18 Years - n/a
Date
Study Start Date: 01 Jan 2025
Estimated Primary Completion Date: 30 Jun 2028
Estimated Study Completion Date: 30 Jun 2028
Study design
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Oct 2024 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| SLE Patients Open-lable arm with SLE patients who received anifrolumab treatment in the frames of NDP in Poland. | - |
